Fresenius Kabi expands production site for medical devices in Dominican Republic

Fresenius Kabi has started work on a major expansion of its production site for medical devices in Haina, Dominican Republic, which will create about 500 new jobs. At a groundbreaking ceremony yesterday attended by the country’s President Danilo Medina, the cornerstone was laid for the approximately 7,400-square-meter (80,000-square-foot) expansion. It will significantly increase capacity in Haina through the addition of new plasma kit assembly lines, injection molding equipment, sterilization units and dedicated warehouse space.

Completion of the expansion is scheduled for late 2019. The new employees, including production workers, technical personnel, engineers and managers, will join a Fresenius Kabi workforce in Haina that currently numbers about 3,000. The total investment is more than €20 million ($25 million).

The Haina plant manufactures and exports apheresis systems for plasma and platelet collection as well as medical devices for blood separation. These products are used, for example, to allow blood components to be separated while the blood is being donated, making it possible for these life-saving donations to be used more quickly and efficiently.

Mats Henriksson, CEO of Fresenius Kabi, said the products manufactured by the company in the Dominican Republic are important in the provision of healthcare far beyond the country. “Our employees here in Haina do an excellent job, and will continue to produce high-quality medical devices that provide healthcare professionals with the equipment they need to help their patients,” Henriksson said.

Also on hand for the ceremony was Dr. Christian Hauer, President Medical Devices Division of Fresenius Kabi. “This expansion will enable us to reach new potential in regard to our production capacities,” Hauer said. “Our strong commitment to our production site in Haina will benefit even more patients, and allow us to play an even greater role in improving the lives of chronically and critically ill people around the world.”


Martin Kunze

Director External Communications
T: +49 (0) 6172 608-2115

For More information visit :

Leave a Reply

Your email address will not be published.